Merck 2Q profit more than doubles

July 29, 2014 by Linda A. Johnson

A big one-time gain and a tax benefit helped drugmaker Merck & Co. more than double its second-quarter profit, raise the lower end of its profit forecast and easily top analysts' expectations.

The maker of popular Type 2 diabetes pill Januvia and cholesterol medicines Vytorin and Zetia said Tuesday that net income increased to $2 billion, or 68 cents per share, from $906 million, or 30 cents per share, in the same quarter a year earlier.

Merck, based in Whitehouse Station, New Jersey, said its earnings, adjusted for one-time gains and costs, were 85 cents per share. The average per-share estimate of analysts surveyed by Zacks Investment Research was for profit of 81 cents.

Merck recorded a gain of $741 million from AstraZeneca PLC, its longtime partner in marketing the British drugmaker's heartburn drugs Nexium and Prilosec. AstraZeneca exercised its option to buy out Merck's interest in the drugs.

The world's fourth-biggest drugmaker reported revenue of $10.93 billion, down 1 percent from $11.01 billion a year ago. That edged past Wall Street expectations of $10.71 billion, according to Zacks.

Sales of Merck's prescription drugs totaled $9.09 billion, down 2 percent as cheaper generic competition cut into sales of some older medicines and sales of its hepatitis C drugs was hurt by new brand-name competition. Sales were led by Type 2 diabetes pills Januvia and Janumet, up 2 percent at $1.58 billion, and Zetia and Vytorin, up 6 percent to a combined $1.13 billion.

Sales of veterinary medicines edged up 2 percent to $872 million. Merck's smallest segment, consumer health products, had the best performance, up 19 percent to $583 million. In May, Merck agreed to sell that to Germany's Bayer for $14.2 billion. It includes Claritin, the Coppertone sun-care line, Dr. Scholl's foot-care products and MiraLAX laxative.

Merck has said it would use the money to invest in business areas with the highest growth potential and beef up its drug pipeline with "external assets." The deal is expected to close in the second half of 2014.

Merck said it expects profit for 2014 of $3.43 to $3.53 per share, excluding one-time items. In January, it forecast earnings of $3.35 to $3.53. It also forecast full-year sales $42.4 billion to $43.2 billion, assuming current exchange rates.

"We delivered a strong first half of the year, making progress in transforming our operating model, fueling innovation and managing costs," CEO Kenneth Frazier said in a statement.

In premarket trading, Merck shares were down 18 cents at $57.97. Merck shares have increased $9.63, or 20 percent, in the last 12 months.

Related Stories

Recommended for you

Netherlands bank customers can get vocal on payments

August 1, 2015

Are some people fed up with remembering and using passwords and PINs to make it though the day? Those who have had enough would prefer to do without them. For mobile tasks that involve banking, though, it is obvious that ...

Power grid forecasting tool reduces costly errors

July 30, 2015

Accurately forecasting future electricity needs is tricky, with sudden weather changes and other variables impacting projections minute by minute. Errors can have grave repercussions, from blackouts to high market costs. ...

Microsoft describes hard-to-mimic authentication gesture

August 1, 2015

Photos. Messages. Bank account codes. And so much more—sit on a person's mobile device, and the question is, how to secure them without having to depend on lengthy password codes of letters and numbers. Vendors promoting ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.